Autolus Therapeutics (AUTL)
NASDAQ:AUTL
Want to see AUTL full AI Analyst Report?
Top Page
Autolus Therapeutics
(NASDAQ:AUTL)
Select Model
Select Model
Rating:57Neutral
Price Target:
$2.00
▲(25.00% Upside)
Action:Reiterated
Date:05/19/26
The score is primarily held back by weak financial performance (large losses and substantial cash burn), despite strong earnings-call signals (reiterated revenue guidance, rapid revenue growth, first positive gross profit) and constructive technical momentum. Valuation support is limited due to negative earnings and no stated dividend.
Positive Factors
Rapid commercial revenue growth
Sustained, large YoY revenue growth from AUCATZYL demonstrates clear commercial traction and product-market fit for the ALL franchise. Reiterated full‑year guidance ($120–$135M) and expanding treatment centers support durable mid‑term revenue visibility and scaling potential.
Negative Factors
High cash burn and limited runway
Persistent, large operating cash outflows require ongoing financing or material margin improvement to avoid dilution. Even with cost actions, current liquidity only extends to Q4‑2027; fundraising or milestone execution will be needed during commercialization, reducing financial flexibility and increasing dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid commercial revenue growth
Sustained, large YoY revenue growth from AUCATZYL demonstrates clear commercial traction and product-market fit for the ALL franchise. Reiterated full‑year guidance ($120–$135M) and expanding treatment centers support durable mid‑term revenue visibility and scaling potential.
Read all positive factors
Autolus Therapeutics (AUTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$497.71M
Dividend YieldN/A
Average Volume (3M)1.57M
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth928.46%
EPS Growth-21.39%
CountryUS
Employees647
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding266,155,800
10 Day Avg. Volume1,839,907
30 Day Avg. Volume1,569,988
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue4.82
Enterprise Value/Gross Profit-43.12
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$8.08Price Target Upside405.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$129.66M
Autolus Therapeutics Business Overview & Revenue Model
Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investig...
How the Company Makes Money
null...
Autolus Therapeutics Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call reflected strong commercial momentum and operational progress: quarterly revenue surged (~191% YoY), the company achieved its first positive gross margin quarter, and production efficiency initiatives target lower per-unit costs and $15M annualized savings in 2027. Real-world data and multiple near- and mid-term clinical readouts underpin a promising pipeline and support expansion into new indications and geographies. Offsetting these positives are continued high net losses, significant cash drawdown (cash runway into Q4 2027), a sizable rise in SG&A to support commercialization, and execution risks related to manufacturing scale-up and European market access. Overall, while financial and execution risks remain, the balance of substantial commercial progress, margin improvement, and clear pipeline milestones leads to a constructive outlook.Positive Updates
Strong Quarter-over-Quarter Revenue Growth
Q1 2026 net product revenue of $26.2M versus $9.0M in Q1 2025, an increase of ~191%, driven by U.S. sales and the start of the U.K. launch (U.K. contribution minimal in Q1).
Negative Updates
High Net Loss Persists
Net loss for Q1 2026 was $71.6M vs ~$70.2M in Q1 2025 (a ~2.0% increase), meaning overall profitability remains a significant challenge at the company level in the near term.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Quarter-over-Quarter Revenue Growth
Q1 2026 net product revenue of $26.2M versus $9.0M in Q1 2025, an increase of ~191%, driven by U.S. sales and the start of the U.K. launch (U.K. contribution minimal in Q1).
Read all positive updates
Company Guidance
Autolus reiterated its 2026 AUCATZYL net product revenue guidance of $120–$135 million (U.S. and U.K.); Q1 product revenue was $26.2M (vs. $9.0M in Q1‑2025) and the company recorded its first‑time positive gross profit of $1.6M with cost of sales of $24.6M, while loss from operations was $59.5M and net loss $71.6M for the quarter; Q1 R&D was $21.2M (down from $26.7M) and SG&A $39.9M (up from $29.5M). Management reported $229.4M in cash, cash equivalents and marketable securities at March 31, 2026 (vs. $300.7M at Dec 31, 2025) and expects that cash to fund operations into Q4‑2027. Operational targets include ~73 active U.S. centers (rising to >80 by year‑end), >10 active U.K. centers, plans to produce ~2× the product in 2026 versus 2025 with staffing at or below prior levels, a 13% workforce reduction and an expected $15M of annualized savings in 2027, and a peak ALL gross profit margin goal of ~65%–70%.Autolus Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.59M | 75.56M | 10.12M | 1.70M | 6.19M | 1.51M |
| Gross Profit | -10.36M | -21.03M | -130.90M | 1.70M | 6.19M | 1.51M |
| EBITDA | -248.06M | -271.60M | -233.07M | -156.77M | -132.24M | -132.47M |
| Net Income | -288.83M | -288.20M | -220.66M | -208.38M | -148.84M | -142.10M |
Balance Sheet | ||||||
| Total Assets | 527.07M | 589.07M | 782.73M | 375.38M | 490.27M | 405.56M |
| Cash, Cash Equivalents and Short-Term Investments | 229.43M | 300.71M | 588.02M | 239.57M | 382.44M | 310.34M |
| Total Debt | 79.96M | 351.59M | 52.63M | 52.97M | 24.26M | 68.01M |
| Total Liabilities | 418.24M | 410.94M | 355.40M | 263.91M | 191.60M | 92.24M |
| Stockholders Equity | 108.83M | 178.13M | 427.32M | 111.47M | 298.67M | 313.32M |
Cash Flow | ||||||
| Free Cash Flow | -291.52M | -303.32M | -241.09M | -156.57M | -123.15M | -126.72M |
| Operating Cash Flow | -273.32M | -283.57M | -206.27M | -145.59M | -112.31M | -117.86M |
| Investing Cash Flow | 314.16M | 158.46M | -394.55M | -10.99M | -10.84M | -8.86M |
| Financing Cash Flow | -6.40M | -4.34M | 589.55M | -883.00K | 223.61M | 284.06M |
Autolus Therapeutics Technical Analysis
Positive
1.60
Price Trends
1.53
Positive
1.53
Positive
1.54
Positive
Market Momentum
0.07
Negative
62.49
Neutral
72.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Positive. The current price of 1.6 is below the 20-day moving average (MA) of 1.67, above the 50-day MA of 1.53, and above the 200-day MA of 1.54, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 62.49 is Neutral, neither overbought nor oversold. The STOCH value of 72.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUTL.
Autolus Therapeutics Risk Analysis
Autolus Therapeutics disclosed 88 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Autolus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $504.34M | -8.36 | -27.09% | ― | ― | -1.14% | |
57 Neutral | $497.71M | -1.70 | -128.53% | ― | 928.46% | -21.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $31.71M | -1.96 | -64.17% | ― | -100.00% | 94.65% | |
48 Neutral | $322.76M | ― | -77.09% | ― | ― | -9.22% | |
47 Neutral | $361.51M | -1.80 | -134.14% | ― | ― | -39.31% | |
44 Neutral | $397.14M | -10.93 | -34.82% | ― | ― | 41.21% |
* Healthcare Sector Average
AUTL
Autolus Therapeutics
1.84
-0.07
-3.66%
TVRD
Tvardi Therapeutics
3.22
-26.54
-89.18%
LRMR
Larimar Therapeutics
3.51
1.30
59.18%
BNTC
Benitec Biopharma
10.82
-4.79
-30.69%
DMAC
Diamedica Therapeutics
5.84
1.67
40.05%
CTNM
Contineum Therapeutics, Inc. Class A
13.09
8.66
195.49%
Autolus Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Autolus Therapeutics Reports Strong Q1 Growth and Outlook
Positive
May 14, 2026
On May 14, 2026, Autolus Therapeutics reported first-quarter 2026 results showing net product revenue of $26.2 million from AUCATZYL, up sharply from $9 million a year earlier, and a first-time positive gross margin in its acute lymphoblastic leuk...
Business Operations and StrategyFinancial Disclosures
Autolus Therapeutics Announces Workforce Reduction and Cost Restructuring
Neutral
Apr 29, 2026
On April 29, 2026, Autolus Therapeutics announced a strategic initiative to streamline operations and cut costs, including a reduction in force that will eliminate about 13% of its workforce across all areas of the business, following employee-rel...
Business Operations and StrategyProduct-Related Announcements
Autolus Highlights ALL Opportunity and AUCATZYL CAR-T Platform
Positive
Apr 8, 2026
On April 8, 2026, Autolus Therapeutics hosted a virtual investor event titled “Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business” to highlight the clinical landscape, unmet needs and commercial opportunity in adult and pedia...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Autolus Highlights AUCATZYL Launch and Pipeline Advancements
Positive
Mar 27, 2026
Autolus Therapeutics reported fourth-quarter 2025 net product revenue of $23.3 million and full-year 2025 revenue of $74.3 million from AUCATZYL, driven by its first year of U.S. launch in adult relapsed or refractory B‑ALL, and confirmed th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.